Report Detail
Global Cancer Nanomedicine Market Growth 2022-2028
- RnM4496131 |
- 01 December, 2022 |
- Global |
- 110 Pages |
- LPI(LP Information) |
- Medical Industry
Nanomedicine is a branch of nanotechnology that uses nanoparticles to diagnose, treat, monitor, and control biological systems. By manipulating materials at the nanoscale, it improves medicine delivery. As a result, nanomedicine has helped treat a wide range of diseases. Nanomedicine is still in its infancy, with numerous products in the works. Nanobiotix has identified 230 nanomedicine products that are either patented or in the early stages of development. 49 of the 230 products are on the market, while the remaining 122 are in clinical trials, either in Phase II or Phase III trials.
The global market for Cancer Nanomedicine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Cancer Nanomedicine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Cancer Nanomedicine players cover Alnylam Pharmaceuticals, Inc, Amgen Inc, Arrowhead Pharmaceuticals, Inc, AstraZeneca and Cadila Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Cancer Nanomedicine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Cancer Nanomedicine market, with both quantitative and qualitative data, to help readers understand how the Cancer Nanomedicine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Cancer Nanomedicine market and forecasts the market size by Type (Inorganic Nanoparticles, Protein Nanoparticles and Polymer Nanoparticles), by Application (Breast Cancer, Pancreatic Cancer, Brain Cancer and Lung Cancer), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Inorganic Nanoparticles
Protein Nanoparticles
Polymer Nanoparticles
Lipid Organic Nanoparticles
Segmentation by application
Breast Cancer
Pancreatic Cancer
Brain Cancer
Lung Cancer
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Alnylam Pharmaceuticals, Inc
Amgen Inc
Arrowhead Pharmaceuticals, Inc
AstraZeneca
Cadila Pharmaceuticals
CELGENE CORPORATION
Celsion Corporation
Genzyme
Merck & Co., Inc
Nippon Kayaku Co.,Ltd
Nanobiotix
Pfizer Inc
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
General Electric
Johnson & Johnson Services, Inc
Teva Pharmaceutical Industries Ltd
Gilead Sciences, Inc
Novartis AG
Chapter Introduction
Chapter 1: Scope of Cancer Nanomedicine, Research Methodology, etc.
Chapter 2: Executive Summary, global Cancer Nanomedicine market size (sales and revenue) and CAGR, Cancer Nanomedicine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Cancer Nanomedicine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Cancer Nanomedicine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Cancer Nanomedicine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Alnylam Pharmaceuticals, Inc, Amgen Inc, Arrowhead Pharmaceuticals, Inc, AstraZeneca, Cadila Pharmaceuticals, CELGENE CORPORATION, Celsion Corporation, Genzyme and Merck & Co., Inc, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Cancer Nanomedicine Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Cancer Nanomedicine by Geographic Region, 2017, 2022 & 2028
- 2.1.3 World Current & Future Analysis for Cancer Nanomedicine by Country/Region, 2017, 2022 & 2028
- 2.2 Cancer Nanomedicine Segment by Type
- 2.2.1 Inorganic Nanoparticles
- 2.2.2 Protein Nanoparticles
- 2.2.3 Polymer Nanoparticles
- 2.2.4 Lipid Organic Nanoparticles
- 2.3 Cancer Nanomedicine Sales by Type
- 2.3.1 Global Cancer Nanomedicine Sales Market Share by Type (2017-2022)
- 2.3.2 Global Cancer Nanomedicine Revenue and Market Share by Type (2017-2022)
- 2.3.3 Global Cancer Nanomedicine Sale Price by Type (2017-2022)
- 2.4 Cancer Nanomedicine Segment by Application
- 2.4.1 Breast Cancer
- 2.4.2 Pancreatic Cancer
- 2.4.3 Brain Cancer
- 2.4.4 Lung Cancer
- 2.4.5 Other
- 2.5 Cancer Nanomedicine Sales by Application
- 2.5.1 Global Cancer Nanomedicine Sale Market Share by Application (2017-2022)
- 2.5.2 Global Cancer Nanomedicine Revenue and Market Share by Application (2017-2022)
- 2.5.3 Global Cancer Nanomedicine Sale Price by Application (2017-2022)
3 Global Cancer Nanomedicine by Company
- 3.1 Global Cancer Nanomedicine Breakdown Data by Company
- 3.1.1 Global Cancer Nanomedicine Annual Sales by Company (2020-2022)
- 3.1.2 Global Cancer Nanomedicine Sales Market Share by Company (2020-2022)
- 3.2 Global Cancer Nanomedicine Annual Revenue by Company (2020-2022)
- 3.2.1 Global Cancer Nanomedicine Revenue by Company (2020-2022)
- 3.2.2 Global Cancer Nanomedicine Revenue Market Share by Company (2020-2022)
- 3.3 Global Cancer Nanomedicine Sale Price by Company
- 3.4 Key Manufacturers Cancer Nanomedicine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Cancer Nanomedicine Product Location Distribution
- 3.4.2 Players Cancer Nanomedicine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Cancer Nanomedicine by Geographic Region
- 4.1 World Historic Cancer Nanomedicine Market Size by Geographic Region (2017-2022)
- 4.1.1 Global Cancer Nanomedicine Annual Sales by Geographic Region (2017-2022)
- 4.1.2 Global Cancer Nanomedicine Annual Revenue by Geographic Region
- 4.2 World Historic Cancer Nanomedicine Market Size by Country/Region (2017-2022)
- 4.2.1 Global Cancer Nanomedicine Annual Sales by Country/Region (2017-2022)
- 4.2.2 Global Cancer Nanomedicine Annual Revenue by Country/Region
- 4.3 Americas Cancer Nanomedicine Sales Growth
- 4.4 APAC Cancer Nanomedicine Sales Growth
- 4.5 Europe Cancer Nanomedicine Sales Growth
- 4.6 Middle East & Africa Cancer Nanomedicine Sales Growth
5 Americas
- 5.1 Americas Cancer Nanomedicine Sales by Country
- 5.1.1 Americas Cancer Nanomedicine Sales by Country (2017-2022)
- 5.1.2 Americas Cancer Nanomedicine Revenue by Country (2017-2022)
- 5.2 Americas Cancer Nanomedicine Sales by Type
- 5.3 Americas Cancer Nanomedicine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Cancer Nanomedicine Sales by Region
- 6.1.1 APAC Cancer Nanomedicine Sales by Region (2017-2022)
- 6.1.2 APAC Cancer Nanomedicine Revenue by Region (2017-2022)
- 6.2 APAC Cancer Nanomedicine Sales by Type
- 6.3 APAC Cancer Nanomedicine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
7 Europe
- 7.1 Europe Cancer Nanomedicine by Country
- 7.1.1 Europe Cancer Nanomedicine Sales by Country (2017-2022)
- 7.1.2 Europe Cancer Nanomedicine Revenue by Country (2017-2022)
- 7.2 Europe Cancer Nanomedicine Sales by Type
- 7.3 Europe Cancer Nanomedicine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Cancer Nanomedicine by Country
- 8.1.1 Middle East & Africa Cancer Nanomedicine Sales by Country (2017-2022)
- 8.1.2 Middle East & Africa Cancer Nanomedicine Revenue by Country (2017-2022)
- 8.2 Middle East & Africa Cancer Nanomedicine Sales by Type
- 8.3 Middle East & Africa Cancer Nanomedicine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Cancer Nanomedicine
- 10.3 Manufacturing Process Analysis of Cancer Nanomedicine
- 10.4 Industry Chain Structure of Cancer Nanomedicine
11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Cancer Nanomedicine Distributors
- 11.3 Cancer Nanomedicine Customer
12 World Forecast Review for Cancer Nanomedicine by Geographic Region
- 12.1 Global Cancer Nanomedicine Market Size Forecast by Region
- 12.1.1 Global Cancer Nanomedicine Forecast by Region (2023-2028)
- 12.1.2 Global Cancer Nanomedicine Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Cancer Nanomedicine Forecast by Type
- 12.7 Global Cancer Nanomedicine Forecast by Application
13 Key Players Analysis
- 13.1 Alnylam Pharmaceuticals, Inc
- 13.1.1 Alnylam Pharmaceuticals, Inc Company Information
- 13.1.2 Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
- 13.1.3 Alnylam Pharmaceuticals, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Alnylam Pharmaceuticals, Inc Main Business Overview
- 13.1.5 Alnylam Pharmaceuticals, Inc Latest Developments
- 13.2 Amgen Inc
- 13.2.1 Amgen Inc Company Information
- 13.2.2 Amgen Inc Cancer Nanomedicine Product Offered
- 13.2.3 Amgen Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Amgen Inc Main Business Overview
- 13.2.5 Amgen Inc Latest Developments
- 13.3 Arrowhead Pharmaceuticals, Inc
- 13.3.1 Arrowhead Pharmaceuticals, Inc Company Information
- 13.3.2 Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Product Offered
- 13.3.3 Arrowhead Pharmaceuticals, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Arrowhead Pharmaceuticals, Inc Main Business Overview
- 13.3.5 Arrowhead Pharmaceuticals, Inc Latest Developments
- 13.4 AstraZeneca
- 13.4.1 AstraZeneca Company Information
- 13.4.2 AstraZeneca Cancer Nanomedicine Product Offered
- 13.4.3 AstraZeneca Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 AstraZeneca Main Business Overview
- 13.4.5 AstraZeneca Latest Developments
- 13.5 Cadila Pharmaceuticals
- 13.5.1 Cadila Pharmaceuticals Company Information
- 13.5.2 Cadila Pharmaceuticals Cancer Nanomedicine Product Offered
- 13.5.3 Cadila Pharmaceuticals Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Cadila Pharmaceuticals Main Business Overview
- 13.5.5 Cadila Pharmaceuticals Latest Developments
- 13.6 CELGENE CORPORATION
- 13.6.1 CELGENE CORPORATION Company Information
- 13.6.2 CELGENE CORPORATION Cancer Nanomedicine Product Offered
- 13.6.3 CELGENE CORPORATION Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.6.4 CELGENE CORPORATION Main Business Overview
- 13.6.5 CELGENE CORPORATION Latest Developments
- 13.7 Celsion Corporation
- 13.7.1 Celsion Corporation Company Information
- 13.7.2 Celsion Corporation Cancer Nanomedicine Product Offered
- 13.7.3 Celsion Corporation Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.7.4 Celsion Corporation Main Business Overview
- 13.7.5 Celsion Corporation Latest Developments
- 13.8 Genzyme
- 13.8.1 Genzyme Company Information
- 13.8.2 Genzyme Cancer Nanomedicine Product Offered
- 13.8.3 Genzyme Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.8.4 Genzyme Main Business Overview
- 13.8.5 Genzyme Latest Developments
- 13.9 Merck & Co., Inc
- 13.9.1 Merck & Co., Inc Company Information
- 13.9.2 Merck & Co., Inc Cancer Nanomedicine Product Offered
- 13.9.3 Merck & Co., Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.9.4 Merck & Co., Inc Main Business Overview
- 13.9.5 Merck & Co., Inc Latest Developments
- 13.10 Nippon Kayaku Co.,Ltd
- 13.10.1 Nippon Kayaku Co.,Ltd Company Information
- 13.10.2 Nippon Kayaku Co.,Ltd Cancer Nanomedicine Product Offered
- 13.10.3 Nippon Kayaku Co.,Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.10.4 Nippon Kayaku Co.,Ltd Main Business Overview
- 13.10.5 Nippon Kayaku Co.,Ltd Latest Developments
- 13.11 Nanobiotix
- 13.11.1 Nanobiotix Company Information
- 13.11.2 Nanobiotix Cancer Nanomedicine Product Offered
- 13.11.3 Nanobiotix Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.11.4 Nanobiotix Main Business Overview
- 13.11.5 Nanobiotix Latest Developments
- 13.12 Pfizer Inc
- 13.12.1 Pfizer Inc Company Information
- 13.12.2 Pfizer Inc Cancer Nanomedicine Product Offered
- 13.12.3 Pfizer Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.12.4 Pfizer Inc Main Business Overview
- 13.12.5 Pfizer Inc Latest Developments
- 13.13 F. Hoffmann-La Roche Ltd
- 13.13.1 F. Hoffmann-La Roche Ltd Company Information
- 13.13.2 F. Hoffmann-La Roche Ltd Cancer Nanomedicine Product Offered
- 13.13.3 F. Hoffmann-La Roche Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.13.4 F. Hoffmann-La Roche Ltd Main Business Overview
- 13.13.5 F. Hoffmann-La Roche Ltd Latest Developments
- 13.14 Takeda Pharmaceutical Company Limited
- 13.14.1 Takeda Pharmaceutical Company Limited Company Information
- 13.14.2 Takeda Pharmaceutical Company Limited Cancer Nanomedicine Product Offered
- 13.14.3 Takeda Pharmaceutical Company Limited Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.14.4 Takeda Pharmaceutical Company Limited Main Business Overview
- 13.14.5 Takeda Pharmaceutical Company Limited Latest Developments
- 13.15 General Electric
- 13.15.1 General Electric Company Information
- 13.15.2 General Electric Cancer Nanomedicine Product Offered
- 13.15.3 General Electric Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.15.4 General Electric Main Business Overview
- 13.15.5 General Electric Latest Developments
- 13.16 Johnson & Johnson Services, Inc
- 13.16.1 Johnson & Johnson Services, Inc Company Information
- 13.16.2 Johnson & Johnson Services, Inc Cancer Nanomedicine Product Offered
- 13.16.3 Johnson & Johnson Services, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.16.4 Johnson & Johnson Services, Inc Main Business Overview
- 13.16.5 Johnson & Johnson Services, Inc Latest Developments
- 13.17 Teva Pharmaceutical Industries Ltd
- 13.17.1 Teva Pharmaceutical Industries Ltd Company Information
- 13.17.2 Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Product Offered
- 13.17.3 Teva Pharmaceutical Industries Ltd Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.17.4 Teva Pharmaceutical Industries Ltd Main Business Overview
- 13.17.5 Teva Pharmaceutical Industries Ltd Latest Developments
- 13.18 Gilead Sciences, Inc
- 13.18.1 Gilead Sciences, Inc Company Information
- 13.18.2 Gilead Sciences, Inc Cancer Nanomedicine Product Offered
- 13.18.3 Gilead Sciences, Inc Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.18.4 Gilead Sciences, Inc Main Business Overview
- 13.18.5 Gilead Sciences, Inc Latest Developments
- 13.19 Novartis AG
- 13.19.1 Novartis AG Company Information
- 13.19.2 Novartis AG Cancer Nanomedicine Product Offered
- 13.19.3 Novartis AG Cancer Nanomedicine Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.19.4 Novartis AG Main Business Overview
- 13.19.5 Novartis AG Latest Developments
14 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Cancer Nanomedicine. Industry analysis & Market Report on Cancer Nanomedicine is a syndicated market report, published as Global Cancer Nanomedicine Market Growth 2022-2028. It is complete Research Study and Industry Analysis of Cancer Nanomedicine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
